Effect of 4-hydroxytamoxifen on the expression of pituitary tumor transforming gene in GH3 prolactinonm cells / 中华神经医学杂志

Objective To investigate the effect of 4-hydroxytamoxifen on the expression of pituitary tumor transforming gene (PTTG) in GH3 prolactinoma cells. Methods RT-PCR and Western blotting were employed to detect the expressions of PTTG mRNA and protein in human GH3 prolaetinoma cells. Different concentrations of estradiol (E2) or 4-hydroxytamoxifen (OHTam) were addedl into the hormone-depleted medium, and the viable cell number and expression levels of PTTG mRNA and protein were measured. Results The growth of OH3 prolaetinoma cells was significantly inhibited in hormone-depleted medium. E2 at a concentration of 1×10<'-8> mol/L obviously promoted the cell growth, the effect of which was inhibited by the application of OHTam (1×10<'-6> mol/L) to cause slowed cell growth. The expressions of PTTG at both the mRNA and protein levels were detected in detected in untreated GH3 prolactinoma cells, and OHTam at the concentration of 1×10<'-6> mol/L significantly inhibited their expressions. Conclusion The growth of GH3 cells is estrogen-dependant and can be inhibited by estrogen antagonist OHTam, which also results in reduced expression of PTTG gene in the cells.

Expression of survivin in invasive pituitary adenoma

To investigate the relationship between survivin expression and invasiveness of pituitary adenoma. A total of 66 patients, on whom trans sphenoidal surgery had been performed between July 2006 and March 2008, were enrolled in our study at the Department of Neurosurgery in Shandong Provincial Hospital and Jinan Central Hospital, Shandong, P. R. China. All patients were divided into the invasion group [n=39], and the non-invasion group [n=27] by assessment of preoperative MRI and intraoperative inspection. Survivin expression was determined by immunohistochemistry. Statistical analysis of survivin expression between the 2 sample groups was accomplished using the chi-square test. Survivin was expressed in 46 [69.7%] of the investigated pituitary adenomas. For invasive pituitary adenoma, survivin staining was positive in 35 [89.7%], only 11 [40.7%] specimens were positive in noninvasive tumors. The chi-square test demonstrated a statistically significant difference in survivin expression between invasive and noninvasive pituitary adenoma [x[2]=14.309, p=0.0002]. Survivin was highly associated with invasive pituitary adenoma, it is likely to serve as a useful tool for confirmation of invasive pituitary adenoma and the gene could be an effective target for pituitary adenoma gene therapy